RESEARCH ATLASRESEARCH > HYPE
PUBLIC RESEARCH EDITION
Immune / inflammation

VIP

Mechanism not verified by source image · Peptide

Evidence at a glance

Each record keeps its own evidence class. Counts are records in this public edition, not a quality score.

Open in the interactive library →Compare with other compounds →

Records (2)

H

Human clinical / research

Human clinical / research

Inhaled VIP in primary pulmonary hypertension

Administration reported for this specific study or labeled indication.

Context: Patients with primary pulmonary hypertension

Human study regimen: Amount: 200 µg/day; Route: Inhaled; Frequency: Daily; Species: Human; Population: Patients with primary pulmonary hypertension

Limitations: Small exploratory pulmonary hemodynamics study using inhaled VIP.

Route: Inhaled

Open this exact record in the library →Suggest a correction
U

Unresolved / evidence gap

Unresolved / evidence gap

VIP excess from tumours: secretory diarrhoea in two case reports (2026)

A 2026 case report describes two VIP-secreting neuroendocrine tumours that caused severe secretory diarrhoea and electrolyte abnormalities; one patient improved after adrenalectomy, the other had persistent symptoms despite debulking and somatostatin analogues.

Context: Two patients; endogenous VIP hypersecretion.

Limitations: Case report of endogenous VIP excess; says nothing about administered VIP or any dose.

Route: Not applicable (endogenous)

Open this exact record in the library →Suggest a correction
CONTINUE THE RESEARCH

Follow the pathway.

These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.

ARA-290 / Cibinetide3 labeled records →KPV2 labeled records →LL-372 labeled records →Thymosin alpha-13 labeled records →
Browse this pathway in the library →

Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.